These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease. Kerkeni M; Weiss IS; Jaisson S; Dandana A; Addad F; Gillery P; Hammami M Thromb Res; 2014 Sep; 134(3):633-8. PubMed ID: 25065554 [TBL] [Abstract][Full Text] [Related]
11. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Miyata T; Fu MX; Kurokawa K; van Ypersele de Strihou C; Thorpe SR; Baynes JW Kidney Int; 1998 Oct; 54(4):1290-5. PubMed ID: 9767546 [TBL] [Abstract][Full Text] [Related]
12. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Handa JT; Verzijl N; Matsunaga H; Aotaki-Keen A; Lutty GA; te Koppele JM; Miyata T; Hjelmeland LM Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):775-9. PubMed ID: 10067983 [TBL] [Abstract][Full Text] [Related]
13. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction. Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505 [TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Hein G; Wiegand R; Lehmann G; Stein G; Franke S Rheumatology (Oxford); 2003 Oct; 42(10):1242-6. PubMed ID: 12777635 [TBL] [Abstract][Full Text] [Related]
15. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Busch M; Franke S; Wolf G; Rohde RD; Stein G; Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751 [TBL] [Abstract][Full Text] [Related]
16. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283 [TBL] [Abstract][Full Text] [Related]
17. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751 [TBL] [Abstract][Full Text] [Related]
18. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. Sugiyama S; Miyata T; Ueda Y; Tanaka H; Maeda K; Kawashima S; Van Ypersele de Strihou C; Kurokawa K J Am Soc Nephrol; 1998 Sep; 9(9):1681-8. PubMed ID: 9727377 [TBL] [Abstract][Full Text] [Related]
19. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: Implications for age-related macular degeneration. Ebrahem Q; Renganathan K; Sears J; Vasanji A; Gu X; Lu L; Salomon RG; Crabb JW; Anand-Apte B Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13480-4. PubMed ID: 16938854 [TBL] [Abstract][Full Text] [Related]
20. Increased levels of advanced glycation end products in human cataractous lenses. Franke S; Dawczynski J; Strobel J; Niwa T; Stahl P; Stein G J Cataract Refract Surg; 2003 May; 29(5):998-1004. PubMed ID: 12781289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]